<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384811</url>
  </required_header>
  <id_info>
    <org_study_id>2014-86-882</org_study_id>
    <nct_id>NCT02384811</nct_id>
  </id_info>
  <brief_title>Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary object of this trial is to evaluate the 2-year local control rate adding
      extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Frequencies of treatment-related adverse event categories by NCI-CTC</measure>
    <time_frame>3 months</time_frame>
    <description>Frequencies of treatment-related adverse event categories by NCI-CTC including Esophagitis,Pneumonitis/Bronchitis,Skin reaction in radiation fields,Nausea/vomiting,Leucopenia,Thrombocytopenia,Anemia,Fatigue.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.
The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes.</description>
    <arm_group_label>Radiation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Joined the study voluntarily and signed informed consent form;

          -  Age 18-75；ECOG 0-2

          -  Esophageal squamous cell carcinoma , radical surgery ≤3 months,R0 resection. The
             operative incision healed well.

          -  T3-4N0M0, T1-4N1-3M0 (according to AJCC2009)

          -  No radiotherapy, chemotherapy or other treatments pre(post)surgery

          -  PS ECOG 0-2

          -  Life expectancy of more than 3 months

          -  Hemoglobin(Hb)≥9 g/dL • WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L • platelet count
             (Pt) ≥100x 109/L • Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN • Renal
             function: creatinine &lt; 1.5 x ULN

          -  No immuno-deficiency

          -  Use of an effective contraceptive for adults to prevent pregnancy.

        Exclusion Criteria:

          -  Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis

          -  Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in
             situ, who survived with no evidence disease for over 3 years

          -  Participation in other interventional clinical trials within 30 days

          -  Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives

          -  Drug addiction, Alcoholism or AIDS

          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior

          -  Unsuitable to be enrolled in the trial in the opinion of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-qing Xiang, M.M</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jiaqing Xiang</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>postoperative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

